Imaging non-motor aspects of Parkinson’s disease

Aarsland, 2005, Neuropathology of dementia in Parkinson’s disease: a prospective, community-based study, Ann Neurol, 58, 773, 10.1002/ana.20635 Abe, 2000, Fatigue in patients with Parkinson’s disease, Behav Neurol, 12, 103, 10.1155/2000/580683 Agid, 1987, Biochemistry of neurotransmitters in Parkinson’s disease, 166 Asahina, 1998, Brain muscarinic recptors in progressive supranuclear palsy and Parkinson’s disease: a positron emission tomographic study, J.Neurol.Neurosurg.Psychiat., 65, 155, 10.1136/jnnp.65.2.155 Berding, 2003, [[123I]beta-CIT SPECT imaging of dopamine and serotonin transporters in Parkinson’s disease and multiple system atrophy, Nuklearmedizin, 42, 31, 10.1055/s-0038-1623903 Bohnen, 2008, Selective hyposmia in Parkinson disease: association with hippocampal dopamine activity, Neurosci Lett, 447, 12, 10.1016/j.neulet.2008.09.070 Bohnen, 2005, Cognitive correlates of cortical cholinergic denervation in Parkinson’s disease and parkinsonian dementia, J Neurol. Braak, 2004, Stages in the development of Parkinson’s disease-related pathology, Cell Tissue Res, 318, 121, 10.1007/s00441-004-0956-9 Braune, 2001, The role of cardiac metaiodobenzylguanidine uptake in the differential diagnosis of parkinsonian syndromes, Clin Auton Res, 11, 351, 10.1007/BF02292766 Burn, 2002, Beyond the iron mask: towards better recognition and treatment of depression associated with Parkinson’s disease, Mov Disord, 17, 445, 10.1002/mds.10114 Chaudhuri, 2006, Non-motor symptoms of Parkinson’s disease: diagnosis and management, Lancet Neurol, 5, 235, 10.1016/S1474-4422(06)70373-8 Colloby, 2006, In vivo SPECT imaging of muscarinic acetylcholine receptors using (R,R) 123I-QNB in dementia with Lewy bodies and Parkinson’s disease dementia, Neuroimage, 33, 423, 10.1016/j.neuroimage.2006.07.026 Doder, 2000, Brain serotonin HT1A receptors in Parkinson’s disease with and without depression measured by positron emission tomography and 11C-WAY100635, Movement Disorders, 15, 213 Edison, 2006, Amyloid deposition and metabolic dysfunction in Alzheimer’s disease and mild cognitive impairment: An 11C-PIB and 18FDG PET study, Neurology, 66, A249 Edison, 2008, Amyloid load in Parkinson’s disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography, J Neurol Neurosurg Psychiatry, 79, 1331, 10.1136/jnnp.2007.127878 Emre, 2003, Dementia associated with Parkinson’s disease, Lancet Neurol, 2, 229, 10.1016/S1474-4422(03)00351-X Fearnley, 1991, Ageing and Parkinson’s disease: Substantia nigra regional selectivity, Brain, 114, 2283, 10.1093/brain/114.5.2283 Gomperts, 2008, Imaging amyloid deposition in Lewy body diseases, Neurology, 71, 903, 10.1212/01.wnl.0000326146.60732.d6 Guttman, 2007, Brain serotonin transporter binding in non-depressed patients with Parkinson’s disease, Eur J Neurol, 14, 523, 10.1111/j.1468-1331.2007.01727.x Guttman, 1997, [11C]RTI-32 PET studies of the dopamine transporter in early dopa-naive Parkinson’s disease: Implications for the symptomatic threshold, Neurology, 48, 1578, 10.1212/WNL.48.6.1578 Haehner, 2007, Olfactory loss may be a first sign of idiopathic Parkinson’s disease, Mov Disord, 22, 839, 10.1002/mds.21413 Hagell, 2009, Towards an understanding of fatigue in Parkinson disease, J Neurol Neurosurg Psychiatry, 80, 489, 10.1136/jnnp.2008.159772 Happe, 2007, Association of daytime sleepiness with nigrostriatal dopaminergic degeneration in early Parkinson’s disease, J Neurol, 254, 1037, 10.1007/s00415-006-0483-6 Hely, 2008, The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years, Mov Disord, 23, 837, 10.1002/mds.21956 Hilker, 2003, [18F]fluorodopa uptake in the upper brainstem measured with positron emission tomography correlates with decreased REM sleep duration in early Parkinson’s disease, Clin Neurol Neurosurg, 105, 262, 10.1016/S0303-8467(03)00058-1 Hilker, 2005, Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways, Neurology, 65, 1716, 10.1212/01.wnl.0000191154.78131.f6 Hitten, 1993, Diurnal effects of motor activity and fatigue in Parkinson’s disease, J Neurol Neurosurg Psychiatry, 56, 874, 10.1136/jnnp.56.8.874 Hoffman, 2000, FDG PET imaging in patients with pathologically verified dementia, J Nucl Med, 41, 1920 Au, 2000, Cortical dysfunction in non-demented Parkinson’s disease patients: A combined 31Phosphorus MRS and 18FDG PET study, Brain, 123, 340, 10.1093/brain/123.2.340 Ito, 2002, Striatal and extrastriatal dysfunction in Parkinson’s disease with dementia: a 6-[18F]fluoro-L-dopa PET study, Brain, 125, 1358, 10.1093/brain/awf134 Kalaitzakis, 2008, Controversies over the staging of alpha-synuclein pathology in Parkinson’s disease, Acta Neuropathol, 116, 125, 10.1007/s00401-008-0381-3 Karlsen, 1999, Fatigue in patients with Parkinson’s disease, Mov Disord, 14, 237, 10.1002/1531-8257(199903)14:2<237::AID-MDS1006>3.0.CO;2-X Kim, 2003, Serotonin transporters in the midbrain of Parkinson’s disease patients: a study with 123I-beta-CIT SPECT, J Nucl Med, 44, 870 Klunk, 2004, Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B, Ann Neurol, 55, 306, 10.1002/ana.20009 Kuhl, 1996, In vivo mapping of cholinergic terminals in normal aging, Alzheimer’s disease, and Parkinson’s disease, Ann Neurol, 40, 399, 10.1002/ana.410400309 Maetzler, 2009, Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics, Neurobiol Dis, 34, 107, 10.1016/j.nbd.2008.12.008 Mayberg, 1989, Frontal lobe hypometabolism is associated with depression in Parkinson’s disease, Neurology., 39, 274 McKeith, 2005, Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium, Neurology, 65, 1863, 10.1212/01.wnl.0000187889.17253.b1 O’Brien, 2009, Diagnostic accuracy of 123I-FP-CIT SPECT in possible dementia with Lewy bodies, Br J Psychiatry, 194, 34, 10.1192/bjp.bp.108.052050 Oka, 2007, Characteristics of orthostatic hypotension in Parkinson’s disease, Brain, 130, 2425, 10.1093/brain/awm174 Remy, 2005, Depression in Parkinson’s disease: loss of dopamine and noradrenaline innervation in the limbic system, Brain, 128, 1314, 10.1093/brain/awh445 Rye, 2000, Daytime sleepiness in Parkinson’s disease, Journal of Sleep Research, 9, 63, 10.1046/j.1365-2869.2000.00201.x Sawada, 2009, Diagnostic accuracy of cardiac metaiodobenzylguanidine scintigraphy in Parkinson disease, Eur J Neurol, 16, 174, 10.1111/j.1468-1331.2008.02372.x Scherfler, 2006, Voxel-wise analysis of diffusion weighted imaging reveals disruption of the olfactory tract in Parkinson’s disease, Brain, 129, 538, 10.1093/brain/awh674 Schifitto, 2008, Fatigue in levodopa-naive subjects with Parkinson disease, Neurology, 71, 481, 10.1212/01.wnl.0000324862.29733.69 Siderowf, 2005, [99mTc]TRODAT-1 SPECT imaging correlates with odor identification in early Parkinson disease, Neurology, 64, 1716, 10.1212/01.WNL.0000161874.52302.5D Walker, 2002, Differentiation of dementia with Lewy bodies from Alzheimer’s disease using a dopaminergic presynaptic ligand, J Neurol Neurosurg Psychiatry, 73, 134, 10.1136/jnnp.73.2.134 Walker, 2007, Dementia with lewy bodies: A comparison of clinical diagnosis, FP-CIT SPECT imaging and autopsy, J Neurol Neurosurg Psychiatry, 78, 1176, 10.1136/jnnp.2006.110122 Weintraub, 2005, Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson’s disease, J Nucl Med, 46, 227 Yamamoto, 2004, Reduction of serotonin transporters of patients with chronic fatigue syndrome, Neuroreport, 15, 2571, 10.1097/00001756-200412030-00002 Yong, 2007, A comparison of cerebral glucose metabolism in Parkinson’s disease, Parkinson’s disease dementia and dementia with Lewy bodies, Eur J Neurol, 14, 1357, 10.1111/j.1468-1331.2007.01977.x